Peer-reviewed veterinary case report
Inflammatory mammary cancer in dogs treated with piroxicam response
By de M Souza, Carlos H et al.·Published in The Canadian veterinary journal = La revue veterinaire canadienne·2009·Instituto Nacional de Proteç, Brazil·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Inflammatory mammary carcinoma in 12 dogs: clinical features, cyclooxygenase-2 expression, and response to piroxicam treatment.
- Species:
- dog
Plain-English summary
A group of dogs with inflammatory mammary carcinoma, a rare and aggressive type of breast cancer, were treated with either traditional chemotherapy or a medication called piroxicam. The dogs treated with piroxicam showed significant improvement and had a much longer survival time, averaging about 185 days, compared to just 7 days for those on chemotherapy. All tumors showed strong expression of a protein called cyclooxygenase-2, which may be linked to the effectiveness of piroxicam. This suggests that piroxicam could be a better option for treating this serious condition in dogs.
People also search for: dog breast cancer treatment · piroxicam for dogs · inflammatory mammary carcinoma in dogs · dog cancer survival rates
Abstract
Canine inflammatory mammary carcinoma (IMC) is a rare, locally aggressive, highly metastatic tumor that is poorly responsive to treatment. The purposes of this study were to retrospectively evaluate the history, signalment, and clinical signs of dogs with IMC; compare the outcome of affected dogs treated with traditional chemotherapy with those treated with piroxicam; evaluate Cox-2 expression of IMC cells; and correlate Cox-2 expression with outcome based on treatment. Strong cyclooxygenase-2 expression was present in all tumors. Improvement in clinical condition and disease stability was achieved in all dogs treated with piroxicam, with mean and median progression-free survival of 171 and 183 days, respectively. Median survival time of 3 dogs treated with doxorubicin-based protocols was 7 days, which was significantly less than that of dogs treated with piroxicam (median, 185 days). In conclusion, piroxicam should be considered as a single agent for the treatment of dogs with inflammatory mammary carcinoma.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/19436636/